Bisphosphonates induce apoptosis in human breast cancer cell lines

Abstract

Breast cancer has a prodigious capacity to metastasize to bone. In women with advanced breast cancer and bone metastases, bisphosphonates reduce the incidence of hypercalcaemia and skeletal morbidity. Recent clinical findings suggest that some bisphosphonates reduce the tumour burden in bone with a consequent increase in survival, raising the possibility that bisphosphonates may have a direct effect on breast cancer cells. We have investigated the in vitro effects of bisphosphonates zoledronate, pamidronate, clodronate and EB 1053 on growth, viability and induction of apoptosis in three human breast cancer cell lines (MDA-MB-231, Hs 578T and MCF-7). Cell growth was monitored by crystal violet dye assay, and cell viability was quantitated by MTS dye reduction. Induction of apoptosis was determined by identification of morphological features of apoptosis using time-lapse videomicroscopy, identifying morphological changes in nucleis using Hoechst staining, quantitation of DNA fragmentation, level of expression of bcl-2 and bax proteins and identification of the proteolytic cleavage of Poly (ADP)-ribose polymerase (PARP). All four bisphosphonates significantly reduced cell viability in all three cell lines. Zoledronate was the most potent bisphosphonate with IC50 values of 15, 20 and 3 microM respectively in MDA-MB-231, MCF-7 and Hs 578T cells. Corresponding values for pamidronate were 40, 35 and 25 microM, whereas clodronate and EB 1053 were more than two orders of magnitude less potent. An increase in the proportion of cells having morphological features characteristic of apoptosis, characteristic apoptotic changes in the nucleus, time-dependent increase in the percentage of fragmented chromosomal DNA, down-regulation in bcl-2 protein and proteolytic cleavage of PARP, all indicate that bisphosphonates have direct anti-tumour effects on human breast cancer cells.

References 45

1. 1.

   Altman R. D., Johnston C. C., Khairi M. R., Wellman H., Serafini A. N., Sankey R. R. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med. 1973;289(26):1379-1384.

   Not in our library10.1056/nejm197312272892601

2. 2.

   Berenson J. R., Lichtenstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M. J. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488-493.

   Not in our library10.1056/nejm199602223340802

3. 3.

   Boise L. H., González-García M., Postema C. E., Ding L., Lindsten T., Turka L. A., Mao X., Nuñez G., Thompson C. B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74(4):597-608.

   Not in our library10.1016/0092-8674(93)90508-n

4. 4.

   Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F. H., Delmas P. D., Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997;57(18):3890-3894.

   Not in our library

5. 5.

   Boonekamp P. M., van der Wee-Pals L. J., van Wijk-van Lennep M. M., Thesing C. W., Bijvoet O. L. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986;1(1):27-39.

   Not in our library

6. 6.

   Bossy-Wetzel E., Newmeyer D. D., Green D. R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J. 1998;17(1):37-49.

   Not in our library10.1093/emboj/17.1.37

7. 7.

   Boyde A., Maconnachie E., Reid S. A., Delling G., Mundy G. R. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc. 1986;(Pt 4):1537-1554.

   Not in our library

8. 8.

   Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.

   Not in our library10.1016/0003-2697(76)90527-3

9. 9.

   Busch M., Rave-Fränk M., Hille A., Dühmke E. Influence of clodronate on breast cancer cells in vitro. Eur J Med Res. 1998;3(9):427-431.

   Not in our library

10. 10.

    Cardone M. H., Roy N., Stennicke H. R., Salvesen G. S., Franke T. F., Stanbridge E., Frisch S., Reed J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282(5392):1318-1321.

    Not in our library10.1126/science.282.5392.1318

11. 11.

    Cory A. H., Owen T. C., Barltrop J. A., Cory J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991;3(7):207-212.

    Not in our library10.3727/095535491820873191

12. 12.

    Coxon F. P., Benford H. L., Russell R. G., Rogers M. J. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol. 1998;54(4):631-638.

    Not in our library

13. 13.

    Dbaibo G. S., Perry D. K., Gamard C. J., Platt R., Poirier G. G., Obeid L. M., Hannun Y. A. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J Exp Med. 1997;185(3):481-490.

    Not in our library10.1084/jem.185.3.481

14. 14.

    Diel I. J., Solomayer E. F., Costa S. D., Gollan C., Goerner R., Wallwiener D., Kaufmann M., Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339(6):357-363.

    Not in our library10.1056/nejm199808063390601

15. 15.

    Frith J. C., Mönkkönen J., Blackburn G. M., Russell R. G., Rogers M. J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997;12(9):1358-1367.

    Not in our library10.1359/jbmr.1997.12.9.1358

16. 16.

    Golstein P. Controlling cell death. Science. 1997;275(5303):1081-1082.

    Not in our library10.1126/science.275.5303.1081

17. 17.

    Hall D. G., Stoica G. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res. 1994;9(2):221-230.

    Not in our library10.1002/jbmr.5650090211

18. 18.

    Hortobagyi G. N., Theriault R. L., Lipton A., Porter L., Blayney D., Sinoff C., Wheeler H., Simeone J. F., Seaman J. J., Knight R. D. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16(6):2038-2044.

    Not in our library10.1200/jco.1998.16.6.2038

19. 19.

    Hughes D. E., MacDonald B. R., Russell R. G., Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989;83(6):1930-1935.

    Not in our library10.1172/jci114100

20. 20.

    Hughes D. E., Wright K. R., Uy H. L., Sasaki A., Yoneda T., Roodman G. D., Mundy G. R., Boyce B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10(10):1478-1487.

    Not in our library10.1002/jbmr.5650101008

21. 21.

    Kanis J. A., Powles T., Paterson A. H., McCloskey E. V., Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19(6):663-667.

    Not in our library10.1016/s8756-3282(96)00285-2

22. 22.

    Kanis J. A., Urwin G. H., Gray R. E., Beneton M. N., McCloskey E. V., Hamdy N. A., Murray S. A. Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med. 1987;82(2A):55-70.

    Not in our library10.1016/0002-9343(87)90488-8

23. 23.

    Kaufmann S. H., Desnoyers S., Ottaviano Y., Davidson N. E., Poirier G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53(17):3976-3985.

    Not in our library

24. 24.

    Lazebnik Y. A., Kaufmann S. H., Desnoyers S., Poirier G. G., Earnshaw W. C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 1994;371(6495):346-347.

    Not in our library10.1038/371346a0

25. 25.

    Lin J. H., Duggan D. E., Chen I. W., Ellsworth R. L. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos. 1991;19(5):926-932.

    Not in our library

26. 26.

    Luckman S. P., Coxon F. P., Ebetino F. H., Russell R. G., Rogers M. J. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res. 1998;13(11):1668-1678.

    Not in our library10.1359/jbmr.1998.13.11.1668

27. 27.

    Löwik C. W., van der Pluijm G., van der Wee-Pals L. J., van Treslong-De Groot H. B., Bijvoet O. L. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res. 1988;3(2):185-192.

    Not in our library10.1002/jbmr.5650030210

28. 28.

    Marzo I., Susin S. A., Petit P. X., Ravagnan L., Brenner C., Larochette N., Zamzami N., Kroemer G. Caspases disrupt mitochondrial membrane barrier function. FEBS Lett. 1998;427(2):198-202.

    Not in our library10.1016/s0014-5793(98)00424-4

29. 29.

    McConkey D. J., Orrenius S. Signal transduction pathways in apoptosis. Stem Cells. 1996;14(6):619-631.

    Not in our library10.1002/stem.140619

30. 30.

    Mundy G. R., Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 1998;339(6):398-400.

    Not in our library10.1056/nejm199808063390609

31. 31.

    Paterson A. H., Powles T. J., Kanis J. A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1):59-65.

    Not in our library10.1200/jco.1993.11.1.59

32. 32.

    Plasmans C. M., Kuypers W., Slooff T. J. The effect of ethane-1-hydroxy-1, 1-diphosphonic acid (EHDP) on matrix induced ectopic bone formation. Clin Orthop Relat Res. 1978;(132):233-243.

    Not in our library

33. 33.

    Powell G. J., Southby J., Danks J. A., Stillwell R. G., Hayman J. A., Henderson M. A., Bennett R. C., Martin T. J. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 1991;51(11):3059-3061.

    Not in our library

34. 34.

    Ryzen E., Martodam R. R., Troxell M., Benson A., Paterson A., Shepard K., Hicks R. Intravenous etidronate in the management of malignant hypercalcemia. Arch Intern Med. 1985;145(3):449-452.

    Not in our library

35. 35.

    Sasaki A., Boyce B. F., Story B., Wright K. R., Chapman M., Boyce R., Mundy G. R., Yoneda T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995;55(16):3551-3557.

    Not in our library

36. 36.

    Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D. D., Golub E., Rodan G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88(6):2095-2105.

    Not in our library10.1172/jci115539

37. 37.

    Selander K. S., Mönkkönen J., Karhukorpi E. K., Härkönen P., Hannuniemi R., Vänänen H. K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol. 1996;50(5):1127-1138.

    Not in our library

38. 38.

    Shipman C. M., Croucher P. I., Russell R. G., Helfrich M. H., Rogers M. J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998;58(23):5294-5297.

    Not in our library

39. 39.

    Shipman C. M., Rogers M. J., Apperley J. F., Russell R. G., Croucher P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997;98(3):665-672.

    Not in our library10.1046/j.1365-2141.1997.2713086.x

40. 40.

    Tewari M., Quan L. T., O'Rourke K., Desnoyers S., Zeng Z., Beidler D. R., Poirier G. G., Salvesen G. S., Dixit V. M. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995;81(5):801-809.

    Not in our library10.1016/0092-8674(95)90541-3

Cited by papers we hold 4

• Tumour macrophages as potential targets of bisphosphonates · 2011
  No notice
• Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours · 2011
  No notice
• Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro · 2003
  No notice
• New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects · 2003
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.